

Prävention, Diagnose und Management von Kieferosteonekrosen (ONJ) während einer osteoprotektiven Therapie onkologischer Patienten

Prof. Dr. med Ingo J. Diel
PD Dr. Dr. med Sven Otto
PD Dr. med Tilman Todenhöfer

- [1] Erna Lesky in: Wiener klinische Wochenschrift 1966; 37:601-604
- [2] Case of Dr John P. Andrews, The Occupational Diseases, W Gilman Thompson, D Appleton & Co, New York, 1914
- [3] London Hospital Medical College Museum
- [4] J. Freyschmidt: Skeletterkrankungen: Klinisch-radiologische Diagnose und Differentialdiagnose. Ausgabe 3, Springer, 2008, ISBN 3-540-45529-9, S. 140
- [5] Khan AA et al. J Bone Miner Res 2015;30:3–23
- [6] Ruggiero SL et al. J Oral Maxillofac Surg. position paper on medication-related osteonecrosis of the jaws—2014 update
- [7] Aljohani S et al. J Oral Maxillofac Surg. 46 (2018) 1515-1525
- [8] Mast G et al. J Oral Maxillofac Surg. 40 (2012) 568-571
- [9] Otto S et al. J Oral Maxillofac Surg. 40 (2012) 303-309
- [10] Roodman GD. N Engl J Med 2004 Apr 15;350(16):1655-64
- [11] Bartl, R., E. Tresckow and C. Bartl (2006). Bisphosphonat-Manual Wirkungen -Indikationen –Strategien, Springer-Verlag.
- [12] Cummings, S.R., et al., N Engl J Med, 2009. 361(8): p. 756-65
- [13] Stopeck AT et al. J Clin Oncol, 2010
- [14] Fizazi K et al. Lancet, 2011. 377 (9768): p. 813-22.
- [15] Stopeck et al. Support Care Cancer 2016 Jan;24(1):447-55
- [16] Christodoulou, C., et al., Oncology, 2009 76(3): p. 209-11
- [17] Bamias et al. J Clin Oncol 2005; 23:8580
- [18] Hoff et al., J Bone Min Res. 2008, 23:836
- [19] Durie et al. NEJM 2005 353:99
- [20] Himmelstein et al. JAMA 2017 317:48
- [21] Diel IJ et al. Crit Rev Haematol Oncol 2007;64:198-207
- [22] Lipton A, et al. Eur J Cancer 2012; 48:3082-92
- [23] Stopeck et al. Support Care Cancer 2016 Jan;24(1):447-55
- [24] Raje et al., Abstract 8005, ASCO 2017
- [25] Qi et al. Int J Clin Oncol 2014, 19:403
- [26] Patel et al. Br Dent J 2018; 224:74
- [27] Nach: Boyle WJ et al., Nature 423:337–42, 2003
- [28] Roodman GD. N Engl J Med 350(16):1655–64, 2004
- [29] Green JR. Oncologist 9(Suppl 4):3–13, 2004
- [30] Mundy GR. Nat Rev Cancer ;2:584–93; 2002
- [31] McClung MR, et al. N Engl J Med 2006;354:821–31
- [32] Huja, F. et al. 2006 Anat Rec A Discov Mol Cell Evol Biol 288(12): 1243-1249
- [33] Walter, Grötz et al. 2007 Supportive Care in Cancer15(2): 197-202
- [34] Ruggiero, Dodson et al. Medication-Related Osteonecrosis of the Jaw - 2014 Update. A.A.o.O.a.M. Surgeons.
- [35] Otto S, et al. Cancer Treat Rev. 2018 Sep;69:177-187
- [36] K. A. Grötz, Wiesbaden, im Auftrag der ASORS; www.onkosupport.de ASORS-Laufzettel empfohlen durch die S3-Leitlinie BP-ONJ (007.091; www.awmf.de)
- [37] Vandone et al. Ann Oncol 2012, 23:193
- [38] Mücke et al. J Craniomaxillofac Surg 2016; 44:1689
- [39] Vescovi et al. Minerva Stomatol 2010;59:181
- [40] Leitlinien DGZMK: Grötz K et al. 2012 S3 Leitlinie Stand 04/2012 – neue LL 2018
- [41] Diel IJ et al. 2007
- [42] Khosla S et al. 2007 J Bone Miner Res. 2007 Oct;22(10):1479-91.
- [43] Yarom N, Fedele S. J Oral Maxillofac Surg. 2010 Mar;68(3):705

- [44] Otto S Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab and New Agents. Springer 2015
- [45] Otto S, et al. J Craniomaxillofac Surg 2015 Jul; 43(6): 837-846
- [46] Van den Wyngaert et al. Ann Oncol. 2009 Feb;20(2):331-6
- [47] Badros et al. J Clin Oncol. 2008 Dec 20;26(36):5904-9
- [48] Nicolatou-Galitis et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Aug;112(2):195-202
- [49] Stanton et al. J Oral Maxillofac Surg. 2009 May;67(5):943-50
- [50] Carlson and Basile et al. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):85-95
- [51] Voss et al. Odontology 2017 Oct;105(4):484-493

- [52] Pautke C et al. J Oral Maxillofac Surg. 2011 69 (1), 84-91
- [53] Otto S. et al. J Craniomaxillofac Surg 2016 Aug;44(8):1073-80
- [54] Pautke C. Treatment of Medication-related osteonecrosis of the jaw. In Otto S. Medication-Related Osteonecrosis of the Jaw: Bisphosphonates, Denosumab and New Agents. Springer 2015:79-92